Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Öhman, Procuritas, Spiltan and others in connection with the acquisition of 51.1 per cent of the shares in Emric AB
Mandate

Vinge advises Öhman, Procuritas, Spiltan and others in connection with the acquisition of 51.1 per cent of the shares in Emric AB

June 10, 2010

Vinge is advising KB Götaberg 20 (Öhman), Investmentbolaget av 1 maj 2009 AB (Procuritas), Investment AB (Spiltan), Norra Brofästet i Sundsvall AB and F. Månsson Invest AB in connection with the acquisition of 50.1 per cent of the shares in Emric AB from Bisnode AB. Emric is one of Sweden's leading providers of software, expert consultancy and outsourcing services to the banking and financial services sector. The acquisition is based on a call option which was issued in connection with Bisnode's purchase of 50.1 per cent of the shares in Emric in 2007.
 
Vinge's team advising the buyers consists of partner Henrik Wenckert and associates Marie Brommesson and Peter Sundgren.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025